Postoperation TSH suppression therapy in differentiated thyroid carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.08.009

Abstract

Hou Xiuxiu, Ge Minghua. Postoperation TSH suppression therapy in differentiated thyroid carcinoma[J]. Journal of International Oncology, 2014, 41(8): 585-587.

［1］ Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors［J］. J Endocrinol Invest, 2012, 35 Suppl 6:3-9. ［2］ Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4):212-236. ［3］ American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2009, 19(11):11671214. ［4］ Alagi′cSmailbegovi′c J, Kucukali′cSelimovi′c E, Seti′c I, et al. Importance of measurement of thyroglobulin and antithyroglobulin antibodies in differentiated thyroid cancer［J］. Coll Antropol, 2012, 36 Suppl 2:33-38. ［5］ McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis:a systematic review and doseresponse metaanalysis［J］. J Clin Endocrinol Metab, 2012, 97(8):2682-2692. ［6］ Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma:what are the targets?［J］. J Clin Endocrinol Metab, 2008, 93(4):1167-1169. ［7］ Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer［J］. Thyroid, 2010, 20(2):135-146. ［8］ Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup［J］. Ann Oncol, 2012, 23 Suppl 7:110-119. ［9］ Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer［J］. J Clin Endocrinol Metab, 2007, 92(7):2610-2615. ［10］ Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction［J］. Endocr Rev, 2008, 29(1):76-131. ［11］ Jonklass J, Davidson B, Bhagat S, et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy［J］. JAMA, 2008, 299(7):769-777. ［12］ Hoang TD, Olsen CH, Mai VQ, et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism:a randomized, doubleblind, crossover study［J］. J Clin Endocrinol Metab, 2013, 98(5):1982-1990. ［13］ Trimboli P, La Torre D, Ceriani L, et al. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?［J］. Horm Metab Res, 2013, 45(9):664-668. ［14］ Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations［J］. J Endocrinol Invest, 2010, 33 Suppl 5:51-56. ［15］ Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH(rhTSH) in 2009:new perspectives in diagnosis and therapy［J］. Q J Nucl Med Mol Imaging, 2009, 53(5):490502. ［16］ Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroidstimulating hormone administration for lowdose radioiodine remnant ablation of differentiated thyroid carcinoma［J］. Thyroid, 2010, 20(2):173-179. ［17］李跃松, 戴军, 陈永伟, 等. 血清TgAb的测定在分化型甲状腺癌中的作用［J］.标记免疫分析与临床, 2010, 17(5):296-298. ［18］ Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methodsStrengths, pitfalls and clinical utility for monitoring TgAbpositive patients with differentiated thyroid cancer［J］. Best Pract Res Clin Endocrinol Metab, 2013, 27(5):701-712. ［19］ Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroidstimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on longterm thyroxine therapy［J］. J Clin Endocrinol Metab, 2010, 95(1):186-193.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.

Postoperation TSH suppression therapy in differentiated thyroid carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments